Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.24 -1.5%	$0.27	$0.20 ▼ $1.48	$64.22M	2.24	1.70 million shs	559,108 shs
CADL Candel Therapeutics	$5.13 -4.3%	$5.17	$3.79 ▼ $14.60	$257.03M	-0.87	1.46 million shs	718,584 shs
CGC Canopy Growth	$1.48 -3.3%	$1.36	$0.77 ▼ $8.65	$272.12M	0.75	6.01 million shs	4.93 million shs
PVLA Palvella Therapeutics	$25.05 -5.2%	$23.67	$6.20 ▼ $29.27	$276.95M	-0.1	70,701 shs	223,836 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-9.66%	-13.99%	-1.64%	-45.39%	-76.36%
CADL Candel Therapeutics	-1.83%	-3.42%	-0.56%	-38.74%	-29.29%
CGC Canopy Growth	-2.55%	+11.68%	+5.52%	+39.09%	-79.84%
PVLA Palvella Therapeutics	+4.34%	+12.47%	+14.27%	-3.82%	+2,641,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.168 of 5 stars	4.2	5.0	2.2	0.8	0.0
CADL Candel Therapeutics	3.1303 of 5 stars	3.5	3.0	4.1	1.7	0.6
CGC Canopy Growth	2.5703 of 5 stars	2.5	2.0	3.3	0.0	1.3
PVLA Palvella Therapeutics	4.0235 of 5 stars	4.6	0.0	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	526.63% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	309.36% Upside
CGC Canopy Growth	1.00	Sell	$2.00	35.14% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	84.77% Upside

Current Analyst Ratings Breakdown

Latest ADAP, CGC, PVLA, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.36	N/A	N/A	$0.17 per share	1.43
CADL Candel Therapeutics	$120K	2,141.90	N/A	N/A	$0.44 per share	11.66
CGC Canopy Growth	$269.00M	1.01	N/A	N/A	$2.72 per share	0.54
PVLA Palvella Therapeutics	$42.81M	6.47	N/A	N/A	$21.66 per share	1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
CADL Candel Therapeutics	-$37.94M	-$1.34	N/A	N/A	N/A	N/A	-629.29%	-173.39%	8/12/2025 (Estimated)
CGC Canopy Growth	-$487.23M	-$4.04	N/A	N/A	N/A	-156.98%	-56.52%	-24.18%	8/8/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	8/13/2025 (Estimated)

Latest ADAP, CGC, PVLA, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CADL Candel Therapeutics	N/A	1.18	1.18
CGC Canopy Growth	0.74	3.52	2.58
PVLA Palvella Therapeutics	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CADL Candel Therapeutics	13.93%
CGC Canopy Growth	3.33%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CADL Candel Therapeutics	16.60%
CGC Canopy Growth	1.30%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	224.05 million	Optionable
CADL Candel Therapeutics	60	50.10 million	18.97 million	Optionable
CGC Canopy Growth	3,150	183.87 million	153.39 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	10.50 million	N/A

ADAP, CGC, PVLA, and CADL Headlines

Recent News About These Companies

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13 at 8:39 AM | msn.com

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings

June 13 at 3:01 AM | americanbankingnews.com

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Average Target Price from Brokerages

June 13 at 2:11 AM | americanbankingnews.com

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.com

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

June 9, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)

June 2, 2025 | marketbeat.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 31, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Toronto Dominion Bank Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

May 27, 2025 | marketbeat.com

Cantor Fitzgerald Predicts PVLA FY2025 Earnings

May 23, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)

May 23, 2025 | marketbeat.com

Cresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)

May 19, 2025 | marketbeat.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.com

Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position

May 16, 2025 | tipranks.com

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...

May 16, 2025 | finance.yahoo.com

Palvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts

May 16, 2025 | marketbeat.com

Q1 2025 Palvella Therapeutics Inc Earnings Call Transcript

May 16, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, CGC, PVLA, and CADL Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 0.00 (-1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.25 +0.01 (+3.18%)

As of 04:19 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Candel Therapeutics NASDAQ:CADL

$5.13 -0.23 (-4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$5.13 0.00 (0.00%)

As of 04:16 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Canopy Growth NASDAQ:CGC

$1.48 -0.05 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.48 +0.01 (+0.34%)

As of 04:21 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Palvella Therapeutics NASDAQ:PVLA

$25.05 -1.37 (-5.19%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time